What the company does
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric …
What the weekly tape is saying
GE9 closed the latest completed week at 215.7 EUR. The 4-week return is -6.4% and the 12-week return is -1.0%. Trend Signal is inactive, Market Dynamics is 0.03. Setup signature: Risk-first tape with a 28/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 250.2 EUR
- Vs Trend Line
- -13.8%
- Fair Value
- 255.4 EUR
- Vs Fair Value
- -15.5%
- 52W High
- 331.0 EUR
- 52W Low
- 203.5 EUR
- Drawdown
- -34.8%
- Range Position
- 9.6%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 0
- 52W Active Breadth
- 0.0%
- Sector Scope
- DE Healthcare
- Sector Rank
- 29 of 80
- Sector Percentile
- 64.6%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
DE Healthcare
- Tracked Peers
- 80
- 4W Rank
- 64 of 80
- Avg 1W
- -1.6%
- Avg 4W
- 1.1%
- Trend Breadth
- 32.5%
- Positive MD
- 43.8%
DE Biotechnology
- Tracked Peers
- 12
- 4W Rank
- 6 of 12
- Avg 1W
- -3.8%
- Avg 4W
- -6.8%
- Trend Breadth
- 25.0%
- Positive RS
- 16.7%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- 0.03
- 4W MD Change
- 132.8%
- Relative Strength
- -
- 4W RS Change
- -
- Expectation
- Undecided
- Probability
- 45.64%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 163
- 13W Average
- 549
- 52W Average
- 557
- Vs 13W
- 0.3x
- Vs 52W
- 0.3x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 4.0%
- 52W Volatility
- 5.2%
- Upside Weeks
- 14
- Downside Weeks
- 17
- Downside Breadth
- 53.1%
- Avg Gain / Loss
- 2.8% / -4.5%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- GER
- Country
- DE
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- EUR
- Market Cap
- 13.9B
Opportunity signals
- Market Dynamics is positive on the latest completed week.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 215.7 EUR | -0.4% | 250.2 EUR | 255.4 EUR | 0.03 | - | 163 | Off |
| 5 Jun 2026 | 216.6 EUR | -4.7% | 251.7 EUR | 256.7 EUR | 0.07 | - | 1.1K | Off |
| 29 May 2026 | 227.2 EUR | -1.6% | 255.5 EUR | 257.9 EUR | 0.00 | - | 51 | Off |
| 22 May 2026 | 231.0 EUR | 0.2% | 259.0 EUR | 259.0 EUR | -0.08 | - | 232 | Off |
| 15 May 2026 | 230.5 EUR | 6.4% | - | 259.9 EUR | -0.10 | - | 704 | Off |
| 8 May 2026 | 216.6 EUR | -4.0% | - | 261.0 EUR | - | - | 656 | Off |
| 1 May 2026 | 225.7 EUR | -1.6% | - | 262.6 EUR | - | - | 124 | Off |
| 24 Apr 2026 | 229.3 EUR | -5.3% | - | 264.1 EUR | - | - | 303 | Off |
| 17 Apr 2026 | 242.1 EUR | 0.7% | - | 265.4 EUR | - | - | 367 | Off |
| 10 Apr 2026 | 240.5 EUR | 2.2% | - | 266.4 EUR | - | - | 735 | Off |
| 3 Apr 2026 | 235.3 EUR | 4.0% | - | 267.5 EUR | - | - | 415 | Off |
| 27 Mar 2026 | 226.3 EUR | 3.9% | - | 269.0 EUR | - | - | 1.6K | Off |
| 20 Mar 2026 | 217.9 EUR | -7.7% | - | 271.0 EUR | - | - | 711 | Off |
| 13 Mar 2026 | 236.2 EUR | 1.9% | - | 273.7 EUR | - | - | 742 | Off |